Recent Acute Myeloid Leukemia News

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive... Continue Reading